Tag: Metastatic Breast Cancer
Seattle Genetics Enhances Portfolio of Solid Tumor Programs by Acquiring Cascadian...
Two Washington-state based companies, Seattle Genetics and Cascadian Therapeutics (previously named Oncothyreon), a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the...
Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...
Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...
Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...
About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...
2017 San Antonio Breast Cancer Symposium will Highlight Several Antibody-Drug Conjugates...
This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...
Pivotal Phase II Study of DS-8201 in Patients with HER2-Positive Metastatic...
Researchers at Daichi Sankyo initiation the DESTINY-Breast01, a pivotal phase II study evaluating the safety and efficacy of DS-8201, an investigational HER2-targeting antibody-drug conjugate...
Growing Drug Development Outsourcing Expected to Increase Demand for Antibody-drug Conjugates
A recent research report published by Technavio, a leading global technology research and advisory company, confirms that the global antibody-drug conjugates (ADC) market will grow...
SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...
Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...
Antibody-drug Conjugate Potential for Metastatic Breast Cancer Treatment Shown Through Results...
In 2012, an estimated 2,975,314 women were living with breast cancer, representing about 12% of all new cancer cases and 25% of all cancers...
